Compare Amgen, Inc. (AMGN) vs VanEck Australian Floating Rate ETF (FLOT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs VanEck Australian Floating Rate ETF — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while VanEck Australian Floating Rate ETF trades at $50.98. The key difference: Amgen, Inc. pays a 2.77% dividend while VanEck Australian Floating Rate ETF pays none. Which is the better fit depends on your goals.
| AMGN | FLOT | |
|---|---|---|
Market Cap | $196.12B | — |
Sector | Health | Sector/Thematic |
52-Week High | $388.16 | $51.09 |
52-Week Low | $271.18 | $50.72 |
Enterprise Value | $241.41B | — |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
FLOT trades at $50.98 with minimal daily movement (+0.02%). Technical indicators show a bullish trend with moving averages supporting upward momentum, though oscillators remain neutral. The ETF maintains consistent dividend distributions, with recent payments of $0.17-$0.18 per share. Market sentiment focuses on floating rate bond exposure amid potential Federal Reserve rate hikes.
FLOT offers exposure to high-quality floating rate bonds with a 4.0% SEC yield, positioning it favorably in a rising rate environment. Key risks include interest rate volatility and credit quality concerns. Analyst consensus leans neutral, with the ETF serving as a cash alternative with modest yield premium over Treasury bills.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About VanEck Australian Floating Rate ETF
FLOT provides exposure to a diversified portfolio of Australian dollar-denominated floating rate notes. It tracks the Bloomberg AusBond Credit FRN 0+ Yr Index, focusing on high-quality, investment-grade bonds from top Australian banks and financial institutions.
Read more on FLOT →
